Brown Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.29M | Buy |
5,274
+2,010
| +62% | +$1.37M | 0.01% | 634 |
|
|
2026
Q1 | $2.52M | Sell |
3,264
-186
| -5% | -$142K | ﹤0.01% | 637 |
|
|
2025
Q4 | $2.66M | Buy |
3,450
+109
| +3% | +$74K | ﹤0.01% | 628 |
|
|
2025
Q3 | $1.88M | Sell |
3,341
-439
| -12% | -$248K | ﹤0.01% | 681 |
|
|
2025
Q2 | $1.98M | Sell |
3,780
-489
| -11% | -$273K | ﹤0.01% | 661 |
|
|
2025
Q1 | $2.71M | Sell |
4,269
-247
| -5% | -$170K | ﹤0.01% | 595 |
|
|
2024
Q4 | $3.22M | Sell |
4,516
-109
| -2% | -$91.5K | ﹤0.01% | 569 |
|
|
2024
Q3 | $4.86M | Sell |
4,625
-37
| -0.8% | -$41.2K | 0.01% | 511 |
|
|
2024
Q2 | $4.9M | Buy |
4,662
+13
| +0.3% | +$12.6K | 0.01% | 501 |
|
|
2024
Q1 | $4.47M | Buy |
4,649
+639
| +16% | +$608K | 0.01% | 509 |
|
|
2023
Q4 | $3.52M | Sell |
4,010
-69
| -2% | -$56.8K | 0.01% | 536 |
|
|
2023
Q3 | $3.36M | Sell |
4,079
-1
| -0% | -$786 | 0.01% | 529 |
|
|
2023
Q2 | $2.93M | Sell |
4,080
-233
| -5% | -$180K | ﹤0.01% | 545 |
|
|
2023
Q1 | $3.54M | Sell |
4,313
-251
| -5% | -$189K | 0.01% | 519 |
|
|
2022
Q4 | $3.29M | Sell |
4,564
-73
| -2% | -$53.9K | 0.01% | 533 |
|
|
2022
Q3 | $3.19M | Buy |
4,637
+1,675
| +57% | +$1.05M | 0.01% | 508 |
|
|
2022
Q2 | $1.75M | Buy |
2,962
+383
| +15% | +$249K | ﹤0.01% | 590 |
|
|
2022
Q1 | $1.8M | Sell |
2,579
-26
| -1% | -$16.4K | ﹤0.01% | 600 |
|
|
2021
Q4 | $1.65M | Buy |
2,605
+198
| +8% | +$122K | ﹤0.01% | 631 |
|
|
2021
Q3 | $1.46M | Buy |
2,407
+3
| +0.1% | +$1.86K | ﹤0.01% | 630 |
|
|
2021
Q2 | $1.34M | Buy |
2,404
+114
| +5% | +$57.8K | ﹤0.01% | 639 |
|
|
2021
Q1 | $1.08M | Buy |
2,290
+9
| +0.4% | +$4.38K | ﹤0.01% | 687 |
|
|
2020
Q4 | $1.1M | Sell |
2,281
-450
| -16% | -$243K | ﹤0.01% | 634 |
|
|
2020
Q3 | $1.53M | Buy |
2,731
+4
| +0.1% | +$2.42K | ﹤0.01% | 544 |
|
|
2020
Q2 | $1.7M | Buy |
2,727
+34
| +1% | +$19.3K | ﹤0.01% | 523 |
|
|
2020
Q1 | $1.31M | Buy |
2,693
+20
| +0.7% | +$8.25K | ﹤0.01% | 529 |
|
|
2019
Q4 | $1M | Buy |
2,673
+127
| +5% | +$42.7K | ﹤0.01% | 634 |
|
|
2019
Q3 | $707K | Buy |
2,546
+1,246
| +96% | +$369K | ﹤0.01% | 683 |
|
|
2019
Q2 | $407K | Sell |
1,300
-790
| -38% | -$263K | ﹤0.01% | 803 |
|
|
2019
Q1 | $859K | Buy |
2,090
+168
| +9% | +$69.2K | ﹤0.01% | 837 |
|
|
2018
Q4 | $717K | Sell |
1,922
-1,238
| -39% | -$453K | ﹤0.01% | 835 |
|
|
2018
Q3 | $1.28M | Sell |
3,160
-8,663
| -73% | -$3.3M | ﹤0.01% | 747 |
|
|
2018
Q2 | $4.08M | Buy |
11,823
+8,898
| +304% | +$2.78M | 0.01% | 479 |
|
|
2018
Q1 | $1.01M | Buy |
2,925
+90
| +3% | +$31.3K | ﹤0.01% | 648 |
|
|
2017
Q4 | $1.06M | Buy |
2,835
+110
| +4% | +$44.5K | ﹤0.01% | 658 |
|
|
2017
Q3 | $1.22M | Sell |
2,725
-21
| -0.8% | -$9.99K | ﹤0.01% | 617 |
|
|
2017
Q2 | $1.35M | Sell |
2,746
-146
| -5% | -$63.9K | ﹤0.01% | 611 |
|
|
2017
Q1 | $1.12M | Buy |
2,892
+252
| +10% | +$93.4K | ﹤0.01% | 617 |
|
|
2016
Q4 | $969K | Buy |
2,640
+678
| +35% | +$258K | ﹤0.01% | 638 |
|
|
2016
Q3 | $788K | Sell |
1,962
-1,540
| -44% | -$618K | ﹤0.01% | 660 |
|
|
2016
Q2 | $1.22M | Buy |
3,502
+1,651
| +89% | +$636K | ﹤0.01% | 566 |
|
|
2016
Q1 | $667K | Sell |
1,851
-69
| -4% | -$28.4K | ﹤0.01% | 653 |
|
|
2015
Q4 | $1.04M | Buy |
1,920
+58
| +3% | +$31.4K | ﹤0.01% | 564 |
|
|
2015
Q3 | $866K | Buy |
1,862
+1,132
| +155% | +$608K | ﹤0.01% | 588 |
|
|
2015
Q2 | $372K | Sell |
730
-1,340
| -65% | -$654K | ﹤0.01% | 694 |
|
|
2015
Q1 | $935K | Sell |
2,070
-169
| -8% | -$71.6K | ﹤0.01% | 564 |
|
|
2014
Q4 | $919K | Sell |
2,239
-799
| -26% | -$314K | ﹤0.01% | 569 |
|
|
2014
Q3 | $1.09M | Buy |
3,038
+104
| +4% | +$34.9K | ﹤0.01% | 532 |
|
|
2014
Q2 | $830K | Buy |
2,934
+35
| +1% | +$10.4K | ﹤0.01% | 587 |
|
|
2014
Q1 | $871K | Buy |
2,899
+16
| +0.6% | +$4.93K | ﹤0.01% | 556 |
|
|
2013
Q4 | $794K | Buy |
2,883
+350
| +14% | +$101K | ﹤0.01% | 554 |
|
|
2013
Q3 | $793K | Buy |
+2,533
| New | +$666K | ﹤0.01% | 543 |
|
Other funds holding REGN
Brown Advisory's REGN Position: Q2 2026 in Review
Brown Advisory increased its Regeneron Pharmaceuticals (REGN) stake by 62% in Q2 2026, buying an estimated $1.37M and bringing the position to 5,274 shares worth $3.29M. The position accounts for 0.01% of the portfolio, ranked #634.
Brown Advisory first reported a position in REGN in Q3 2013 and has held it in 52 quarters since. The position peaked at $4.9M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Brown Advisory held 5,274 shares of Regeneron Pharmaceuticals worth $3.29M as of Q2 2026.
- Brown Advisory bought 2,010 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.37M.
- Regeneron Pharmaceuticals made up 0.01% of Brown Advisory's portfolio in Q2 2026, its #634 holding.
- Brown Advisory first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
- Brown Advisory's Regeneron Pharmaceuticals position peaked at $4.9M in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.